Eiropas Savienība -
latviešu -
EMA (European Medicines Agency)
vumerity
biogen netherlands b.v. - diroximel fumarate (biib098) - multiplā skleroze, recidivējoši-pārskaitot - imūnsupresanti - vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see section 5. 1 for important information on the populations for which efficacy has been established).
Eiropas Savienība -
latviešu -
EMA (European Medicines Agency)
ronapreve
roche registration gmbh - casirivimab, imdevimab - covid-19 virus infection - un imūnglobulīni, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. skatīt nodaļas 4. 4 un 5.
Eiropas Savienība -
latviešu -
EMA (European Medicines Agency)
fingolimod mylan
mylan ireland limited - fingolimod hidrohlorīds - multiplā skleroze, recidivējoši-pārskaitot - imūnsupresanti - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 un 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
Eiropas Savienība -
latviešu -
EMA (European Medicines Agency)
apexxnar
pfizer europe ma eeig - pneumococcal polysaccharide serotype 1, pneumococcal polysaccharide serotype 3, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 5, pneumococcal polysaccharide serotype 6a, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 7f, pneumococcal polysaccharide serotype 8, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 10a, pneumococcal polysaccharide serotype 11a, pneumococcal polysaccharide serotype 12f, pneumococcal polysaccharide serotype 14, pneumococcal polysaccharide serotype 15b, pneumococcal polysaccharide serotype 18c, pneumococcal polysaccharide serotype 19a, pneumococcal polysaccharide serotype 19f, pneumococcal polysaccharide serotype 22f, pneumococcal polysaccharide serotype 23f, pneumococcal polysaccharide serotype 33f - pneimokoku infekcijas - vakcīnas - active immunisation for the prevention of invasive disease and pneumonia caused by streptococcus pneumoniae in individuals 18 years of age and older. skatīt nodaļas 4. 4 un 5. 1, lai iegūtu informāciju par aizsardzību pret specifiskiem pneimokoku serotipiem. apexxnar should be used in accordance with official recommendations. .